|
|
|
European Biopharmaceutical Review
|
| As competition continues to grow within the pharmaceutical industry, companies that trade on an international scale will need to find new ways to view their market, says Gary Muddyman of Conversis
Pharmaceutical companies, for so long highly successful in R&D and international marketing, are facing broader challenges in the fight to retain profit levels in an increasingly competitive global market. Companies currently trading within the $400 billion plus pharmaceutical industry are experiencing an unprecedented level of global competition, as well as demand for increased customisation, volatile end-consumer demand and shorter product lifecycles. To make the situation even more complex, the pharmaceutical supply chain now covers many countries where different customs and cultures come into effect and distribution is organised over various tiers. As a result, lack of co-operation or collaboration can be highly disruptive – particularly where companies are expected to react immediately to sudden changes in demand.
Modern pharmaceutical companies are having to reach an increasingly sophisticated customer, whilst bringing products to market within much shorter timescales. As a result, there is currently a renewed focus on speed-to-market to support the R&D and |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
3rd African Regulatory Conference (ARC)
3-4 May 2012, Accra, Ghana
The African Regulatory Conference offers the opportunity for key stakeholders active on the continent, including representatives from Ministry of Health, local and multinational pharmaceutical companies, to meet to exchange views, discuss topics of interest and identify focus areas for ongoing efforts to increase patient access to new and improved medicines.
More info >> |
|
 |
News and Press Releases |
 |
AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC
AMRI, a global contract services organization, announced today that it has entered into a preferred provider agreement with BioPontis Alliance LLC. The agreement is aimed at supporting BioPontis’ mission to bridge the gap between early-stage research and technologies being discovered and developed in academia and other research entities. AMRI will provide its services in small molecule discovery, development, and manufacturing in BioPontis’ drug discovery research programs. The agreement also supports the need for proof-of-concept data that is required in the current pharmaceutical company licensing environment. The goal of BioPontis Alliance is to identify promising early stage product opportunities and utilize a preferred network of CROs and leading research companies to apply appropriate expertise to develop these opportunities enough to attract pharmaceutical company licensing partners.
More info >> |
|
|
